-
1.发明申请公开(公告)号：US20220002248A1
公开(公告)日：2022-01-06
申请号：US17281368
申请日：2019-09-30
发明人： Zhe WANG , Zhihong ZENG , Rongzhen JIANG
IPC分类号： C07D211/74
摘要： The present invention relates to an MDM2 inhibitor, a preparation method therefor, a pharmaceutical composition thereof, and the use thereof. Specifically, the present invention relates to a compound represented by formula I. The compound has excellent MDM2 inhibitory activities, and can be used for preparing a pharmaceutical composition for treating cancers and other diseases related to MDM2 activities, particularly p53 wild-type cancer.
-
2.发明申请公开(公告)号：US20220380384A1
公开(公告)日：2022-12-01
申请号：US17421819
申请日：2020-01-10
发明人： Zhe WANG , Zhihong ZENG , Lei ZHANG
IPC分类号： C07D513/04 , C07D207/36 , A61P31/20
摘要： The invention relates to an internal cyclic sulphiamidine amide-aryl amide compound and a use thereof for treating hepatitis B. Specifically, disclosed is a compound that may act as an HBV replication inhibitor and that has a structure represented by chemical formula (L), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, a hydrate or a solvent thereof. See the description for detailed definitions of each group. The present invention also relates to a pharmaceutical composition containing the compound and a use thereof for treating hepatitis B.
-
公开(公告)号：US20190382408A1
公开(公告)日：2019-12-19
申请号：US16480174
申请日：2018-01-23
发明人： Zhe WANG , Guoqin FAN , Sai YANG , Zhihong ZENG
IPC分类号： C07D487/04
摘要： Provided is a selective JAK kinase selective inhibitor and a preparation method and the use thereof. In particular, provided is a compound having the structure as shown in chemical formula (I) as a JAK kinase inhibitor or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt, a hydrate or a solvate thereof.
-
-
搜索结果
3 条记录 (耗时 0.013 秒)
